Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.46 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362134 | 1.00 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL5155914 | 0.86 | MAPT (0.61) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL11443651 | 0.83 | MEN1 (0.62) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL15172875 | 0.83 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2060733 | 0.81 | ALDH1A1 (0.61) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10173106 | 0.81 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2244450 | 0.81 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL31490986 | 0.81 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10173135 | 0.81 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL31430630 | 0.81 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025071094-A1 | USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY | 부산대학교 산학협력단 | 2025-04-03 | — | — | WO | claimed |
| WO-2025071094-A1 | USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY | 부산대학교 산학협력단 | 2025-04-03 | — | — | WO | disclosed |
| CN-117843579-A | Benzo heterocycle coupled catechol derivative and preparation method and application thereof | 暨南大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-115167076-A | Photosensitive resin composition and photosensitive dry film resist laminate | 杭州福斯特电子材料有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| CN-113185511-B | Pyrimidine compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-04-26 | — | — | CN | disclosed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-0442323-A2 | Silver halide color reversal photographic material capable of providing interimage effect | FUJI PHOTO FILM CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| EP-0436027-A1 | METHOD OF TREATING SILVER HALIDE PHOTOGRAPHIC MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |
| US-5006444-A | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0420005-A1 | high contrast silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0398285-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1990-11-22 | — | — | EP | disclosed |
| EP-0395069-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0393720-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0335319-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4737442-A | INCLUDING A SENSITIZER AND A BLOCKED DEVELOPMENT RESTRAINER; FREE OF BLACK SPOTS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-04-12 | — | — | US | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885SMN1; SMN2 3582/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885SMN1; SMN2 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.